Target Price | $23.46 |
Price | $8.64 |
Potential |
171.53%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Immunome Inc 2026 .
The average Immunome Inc target price is $23.46.
This is
171.53%
register free of charge
$39.90
361.81%
register free of charge
$20.20
133.80%
register free of charge
|
|
A rating was issued by 15 analysts: 14 Analysts recommend Immunome Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2026 of
171.53%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 9.04 | 4.91 |
35.52% | 45.73% | |
EBITDA Margin | -1,680.20% | -4,054.22% |
733.26% | 141.29% | |
Net Margin | -3,240.71% | -4,000.45% |
325.38% | 23.44% |
10 Analysts have issued a sales forecast Immunome Inc 2025 . The average Immunome Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Immunome Inc EBITDA forecast 2025. The average Immunome Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Immunome Inc Analysts have issued a net profit forecast 2025. The average Immunome Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.00 | -2.26 |
7.06% | 54.80% | |
P/E | negative | |
EV/Sales | 88.56 |
11 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
Lake Street |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
LifeSci Capital |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
Analyst Rating | Date |
---|---|
Locked
Lake Street:
Locked
➜
Locked
|
Apr 02 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
LifeSci Capital:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 14 2024 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.